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INHIBITORY INTERACTIONS BETWEEN HMGB1 AND HEME
OXYGENASE-1 PATHWAYS IN OSTEOARTHRITIC
SYNOVIOCYTES
I. García-Arnandis1, I. Guillén1,2, M.A. Castejón3, M. Alcaraz1
1Univ. of Valencia, Dept. Pharmacology, Burjasot, Spain;
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Purpose: Extracellular high mobility group box 1 (HMGB1) has
been demonstrated to participate in inﬂammatory processes in
joint diseases. Activation of osteoarthritic synoviocytes by pro-
inﬂammatory cytokines results in HMGB1 translocation and re-
lease. We have shown recently a potential modulation of HMGB1
by heme oxygenase-1 (HO-1). In this study, we have examined the
interactions between both pathways in osteoarthritic synoviocytes.
Methods: Synovial tissue samples were obtained from 15 os-
teoarthritic patients undergoing total knee joint replacement. Syn-
oviocytes were obtained by digestion with collagenase and cul-
tured until third passage. Cells were treated with human recombi-
nant HMGB1 (15 ng/ml) in the presence or absence of IL-1β (100
U/ml). HO-1 was induced by cobalt protoporphyrin IX (CoPP).
Lentiviral HO-1.ﬂag vector was also used for HO-1 overexpres-
sion. HO-1 gene silencing was achieved by using a speciﬁc siRNA.
Gene expression was analyzed by quantitative PCR and protein
expression by Western Blot and ELISA. HMGB1 translocation into
the cytoplasm was studied by immunoﬂuorescence.
Results: Treatment of synoviocytes with HMGB1 down-regulated
HO-1. This effect was potentiated by IL-1β and accompanied
by a signiﬁcant increase in matrix metalloproteinase (MMP)-1
and MMP-3 gene expression and activity. Conversely, induction
of HO-1 by CoPP in the presence of IL-1 β led to reduced
expression of both protein and mRNA of HMGB1. These effects
were accompanied by a signiﬁcant reduction in gene expression
of MMP-1 and MMP-3, and MMP activity. The consequences
of HO-1 induction were counteracted by HO-1 gene silencing.
Interestingly, we observed a marked reduction in the translocation
of HMGB1 from the nucleus into the cytoplasm. Transfection with
lentiviral HO-1.ﬂag vector conﬁrmed the inhibitory effect of HO-1
on HMGB1 translocation.
Conclusions: We have provided direct evidence that HO-1 inhibits
the translocation of HMGB1 into the cytoplasm. Our data indicate
a reciprocal negative regulation between HO-1 and HMGB1 path-
ways in osteoarthritic synoviocytes.
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RELATIONSHIP OF WEIGHT CHANGE WITH CHANGE IN
KNEE PAIN AND FUNCTION IN PERSONS WITH
SYMPTOMATIC RADIOGRAPHIC KNEE OSTEOARTHRITIS:
ONE-YEAR FOLLOW-UP DATA FROM THE
OSTEOARTHRITIS INITIATIVE
M.C. Hochberg1, K. Favors1, D. Bujak1, T. Niculescu1,
S. Bartlett2, J. Bathon2, J. Sorkin1
1Univ. of Maryland, Baltimore, MD; 2The Johns Hopkins Univ.,
Baltimore, MD
Purpose: Overweight is a major risk factor for the development
and progression of knee osteoarthritis (OA) and weight loss is
recommended as part of the non-pharmacologic management of
patients with knee OA. This analysis examined the relationship
between weight change and change in self-reported symptoms
and function and physical performance in adults with symptomatic
radiographic knee OA over one year.
Methods: Data for this analysis were obtained from the
Osteoarthritis Initiative (OAI) public access database (http://
www.oai.ucsf.edu). Speciﬁcally, we examined data from the base-
line and 12-month follow-up visits for subjects with symptomatic
radiographic knee OA enrolled in the OAI Progression subcohort.
Subjects completed the Western Ontario McMaster Osteoarthritis
Index (WOMAC) and Knee Osteoarthritis Outcome Score (KOOS)
at both visits. Weight was measured with a balance beam scale
and physical performance was measured with a timed 20-meter
walk at both visits; height was measured with a stadiometer at
baseline. Names and dosage of medications and supplements
were recorded at both visits by trained personnel. Correlations be-
tween change in weight and change in outcomes were examined
in unadjusted and multiple variable adjusted models using gener-
alized estimating equations to control for the correlation between
knees in subjects with both knees involved at baseline. In addition,
subjects were categorized into tertiles based on weight change
over one year and the change in outcomes was examined across
the tertiles of weight change using analysis of variance.
Results: Of 1388 subjects enrolled in the Progression subcohort,
1189 (85.7%) attended the 12-month follow-up visit and were
included in this analysis. The mean (SD) age at baseline was
61.4 (9.1) years; 658 (55.3%) were women and 862 (72.5%) were
white. The mean weight and body mass index (BMI) at baseline
were 86.1 (16.0) kg and 30.1 (4.8) kg/m2, respectively. Over an
average of 12 months, the mean (SD) weight change was -0.31
(4.24) kg; mean (SD) weight change was -4.37 (3.97) kg, -0.03
(0.72) kg and 3.49 (2.58) kg for the tertile that lost weight, had
stable weight and gained weight, respectively. In analyses adjusted
for age, sex, race and use of analgesics and/or antiinﬂammatory
drugs at each visit, weight change was signiﬁcantly correlated with
change in both WOMAC function and WOMAC total as well as
20-meter walk speed (see Table 1). Analyses comparing change
in outcomes across tertiles revealed trends for associations with
WOMAC function and 20-minute walk speed (P < 0.10) with
greater improvement in those with either stable weight or weight
loss compared to those who gained weight (see Table 2).
Table 1. Correlations of Weight Change with Clinical Outcomes
Clinical Outcome Correlation
WOMAC Pain 0.004
WOMAC Function 0.067 (P = 0.02)
WOMAC Total 0.058 (P = 0.04)
KOOS Symptoms -0.032
KOOS Pain -0.021
KOOS Function -0.033
KOOS Quality of Life -0.020
20-meter walk speed -0.065 (P < 0.03)
Change in Clinical Outcomes (mean [SD]) by Tertile of Weight Change
Clinical Outcome Weight loss Weight stable Weight gain
(N=398) (N=396) (N=395)
WOMAC Pain -0.61 (3.34) -0.70 (3.03) -0.59 (3.10)
WOMAC Function -2.33 (10.90) -2.26 (9.46) -0.88 (9.39)
WOMAC Total -3.28 (14.65) -3.39 (12.64) -1.70 (12.78)
KOOS Symptoms 2.61 (14.14) 4.19 (13.92) 2.53 (13.36)
KOOS Pain 4.39 (16.52) 4.83 (15.26) 3.79 (15.37)
KOOS Function 4.54 (18.52) 4.88 (21.34) 3.73 (22.19)
KOOS Quality of Life 5.09 (16.89) 3.67 (17.00) 4.34 (17.21)
20-meter walk speed 0.01 (0.15) 0.01 (0.14) -0.01 (0,15)
Conclusions: These data support an association between weight
loss and improvement in function measured by both self-report and
performance but not improvement in pain and other symptoms.
Limitations of this analysis include a low level of symptoms and
physical dysfunction at baseline and a small amount of weight
change over 12 months. Further analyses of 24-month follow-up
data will be completed when these data become available.
